Pancytopenia Management

Introduction to Pancytopenia

Pancytopenia is characterized by a decrease in all three main cellular elements of the blood: red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia), which can lead to significant morbidity and mortality through anemia, neutropenia, and thrombocytopenia, as reported by the American Society of Clinical Oncology 1, 2
The American Society of Hematology recommends that the management of pancytopenia should be directed at the underlying cause, with appropriate supportive care measures implemented while diagnostic workup is underway, although the exact protocol may vary based on the specific underlying condition and patient factors 3

A complete blood count with differential, peripheral blood smear examination, coagulation tests, and other specific tests such as serum ferritin, iron, and total iron binding capacity, vitamin B12 and folate levels, are essential for identifying the underlying cause of pancytopenia, with the peripheral blood smear being the first diagnostic test to identify morphological abnormalities 3, 4, 5

The following initial workup is recommended for pancytopenia:

Test	Recommendation
Complete blood count with differential	American Society of Hematology [5]
Coagulation tests	International Society on Thrombosis and Haemostasis [5]
Serum ferritin, iron, and total iron binding capacity	National Comprehensive Cancer Network [6]
Vitamin B12 and folate levels	National Comprehensive Cancer Network [7]
Liver function tests	National Comprehensive Cancer Network [7]
Renal function tests	National Comprehensive Cancer Network [7]
Copper and ceruloplasmin levels (if copper deficiency is suspected)	National Comprehensive Cancer Network [7]

Bone marrow biopsy with immunohistochemical stains is a crucial diagnostic tool for pancytopenia, helping to identify underlying conditions such as myelodysplastic syndromes or aplastic anemia, as recommended by the College of American Pathologists 3, 8

For immune-mediated pancytopenia, the American College of Rheumatology recommends corticosteroids (prednisone 1-2 mg/kg/day) as first-line treatment, with a response rate of 70-81% for TPO receptor agonists (romiplostim, eltrombopag) in refractory cases 3, 9
The National Comprehensive Cancer Network recommends induction chemotherapy and consideration of hematopoietic stem cell transplantation for acute leukemias, with the goal of achieving complete remission 3
For myelodysplastic syndromes, the International Prognostic Scoring System (IPSS) or IPSS-R risk categories guide therapeutic options, with hypomethylating agents such as azacitidine being a common treatment option 3, 10, 11
Consider patient age, performance status, and comorbidities when planning treatment, according to the American College of Physicians 10

The American Society of Hematology recommends red blood cell transfusions for symptomatic anemia or hemoglobin <7-8 g/dL, platelet transfusions for active bleeding or platelet count <10,000/μL, and empiric broad-spectrum antimicrobial therapy for febrile neutropenia 3, 12
Antifibrinolytics may be used for severe bleeding in patients with thrombocytopenia, and granulocyte colony-stimulating factor (G-CSF) may be considered in selected cases of neutropenia 3
Supportive care measures include transfusions of red blood cells and platelets, broad-spectrum antibiotics for febrile neutropenia, and hematopoietic growth factors in selected cases, with regular monitoring of complete blood counts and adjustment of treatment as needed, as recommended by the American Society of Clinical Oncology 7, 12
Infection prevention measures, such as strict hand hygiene and neutropenic precautions, and bleeding precautions should be implemented in patients with pancytopenia, as recommended by the American Society of Clinical Oncology 12

The European Society for Medical Oncology recommends TPO-receptor agonists (romiplostim, eltrombopag) for refractory thrombocytopenia, with response rates of 79-88%, and combination chemotherapy may be effective in some chronic refractory cases 3
Hematopoietic stem cell transplantation may be considered for severe refractory cases, although it carries significant risks, and the risk-benefit ratio of aggressive therapies must be carefully weighed 3

The Society for Immunotherapy of Cancer recommends permanently discontinuing the immune checkpoint inhibitor and providing aggressive immunosuppression, including prednisone 1-2 mg/kg/day ± rituximab (375 mg/m² weekly for 4 weeks) and/or cyclophosphamide (1-2 mg/kg/day), for immune checkpoint inhibitor-related pancytopenia 13

Weekly complete blood counts during the first month of treatment, twice monthly for the second and third months, and monthly thereafter or more frequently if dosage alterations are necessary, are recommended to monitor the patient's response to treatment and adjust the treatment plan as needed, as reported by the European League Against Rheumatism 9 and the American Society of Clinical Oncology 1, 12
Clear written instructions should be provided to patients on when to seek medical attention, including symptoms such as fever, bleeding, or worsening symptoms, to ensure prompt recognition and management of potential complications, as recommended by the American Academy of Family Physicians 1 and the American Society of Clinical Oncology 12